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Background:  Apixaban is an oral, direct and selective factor Xa inhibitor under development for secondary prevention in acute coronary syndrome 
(ACS).
Methods:  Apixaban’s effect on biomarkers of inflammation and coagulant regulatory proteins was assessed in a randomized, double-blinded, 
placebo-controlled phase 2 dose-ranging trial. Samples were obtained at baseline , week 3 and week 26 in 1715 patients with ST-segment elevation 
or non-ST elevation ACS who received apixaban (5-20mg daily) or placebo. Apixaban plasma concentrations were measured directly by LC/MS/MS, 
and anti-Xa activity was determined with a chromogenic assay using an apixaban calibrator.
Results: There was a strong, direct and linear relationship between apixaban plasma concentration and anti-Xa activity (r= 0.97 ). High sensitivity 
(hs) C-reactive protein (CRP) (p<0.0001) fibrinogen, (p<0.0001), soluble CD-40Ligand (sCD40L) (p<0.0001) and myeloperoxidase (MPO) (p 
=0.00001) decreased over time from elevated baseline values in all groups. Tissue factor pathway inhibitor (TFPI) increased over time (p<0.0001). 
The changes were greater at week 26 compared with week 3 across increasing quartiles of apixaban plasma concentration and anti-Xa activity( 
figure ).An apixaban level between 100 and 200ng/ml, achieved with the 10mg total daily doses investigated in APPRAISE-2, AVEROES, and 
ARISTOTLE was associated with maximal suppression of hs-CRP (p=0.03), CD40L (p=0.01) and MPO (p=0.04) at 26 weeks of treatment.
Conclusions:  Apixaban - an oral, direct and selective factor Xa inhibitor, in addition to its predicted anticoagulant effects may also attenuate 
leukocyte-and platelet-mediated inflammation and upregulate intrinsic anticoagulant activity, supporting the pleotropic properties of factor Xa.
